Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.49 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.49 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.48 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.48 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7091596 | 0.86 | KMT2A (0.57) | MEN1KMT2AP2RX4KCNJ6KCNJ5 | |
| SCHEMBL7120711 | 0.84 | MEN1 (0.57) | MEN1KMT2AMAPK1CYP1A2CYP2D6 | |
| SCHEMBL7088236 | 0.77 | KMT2A (0.50) | MEN1KMT2ARAB9AP2RX4KCNJ6 | |
| SCHEMBL7090807 | 0.76 | KCNJ5 (0.58) | MEN1KMT2AMAPK1P2RX4KCNJ6 | |
| SCHEMBL24686766 | 0.76 | MEN1 (0.57) | MEN1KMT2AP2RX4KCNJ6KCNJ5 | |
| SCHEMBL12323598 | 0.75 | KMT2A (0.67) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7085535 | 0.74 | ALDH1A1 (0.47) | MEN1KMT2AMAPK1HPGDRAB9A | |
| SCHEMBL7085721 | 0.74 | KMT2A (0.57) | MEN1KMT2ARAB9AP2RX4KCNJ6 | |
| SCHEMBL5623718 | 0.73 | CYP1A2 (0.65) | MEN1KMT2ACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7084931 | 0.72 | CYP1A2 (0.38) | MEN1KMT2AMAPK1CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | MERCK PATENT GMBH (DE) | 2003-09-11 | — | — | US | disclosed |
| US-6559185-B2 | Nitromethyl ketone compounds having aldose reduction inhibiting properties and methods for their use | MERCK PATENT GMBH (DE) | 2003-05-06 | — | — | US | disclosed |
| US-20030069312-A1 | Antidiabetic agents | LARDY CLAUDE (FR) | 2003-04-10 | — | — | US | disclosed |
| US-6043281-A | ALDOSE REDUCTASE INHIBITORS; TREATMENT OR PREVENTION OF COMPLICATIONS OF DIABETES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2000-03-28 | — | — | US | disclosed |
| US-5932765-A | REDUCTASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT (DE) | 1999-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069312-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GPR119 | MEN1 3488/4885KMT2A 3657/4885MAPK1 1514/4885 |
| US-20030171422-A1 | New nitromethyl ketones, process for preparing them and compositions containing them | AKR1B1, AKR1A1, AKR1C1 | MEN1 3542/4885KMT2A 1302/4885MAPK1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.